# Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma

> **NCT02736266** · PHASE2 · COMPLETED · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 174 (actual)

## Conditions studied

- Urothelial Bladder Carcinoma

## Interventions

- **DRUG:** Pembrolizumab (MK-3475)

## Key facts

- **NCT ID:** NCT02736266
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-27
- **Primary completion:** 2018-10-20
- **Final completion:** 2022-09-23
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2023-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02736266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02736266, "Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT02736266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*